Patents
Literature
32 results about "Biological pacemaker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Generally speaking, a biological pacemaker is one or more types of cellular components that, when "implanted or injected into certain regions of the heart," produce specific electrical stimuli that mimic that of the body's natural pacemaker cells. It's indicated for issues such as heart block, slow heart rate, and asynchronous heart ventricle contractions.
Biological pacemaker
Disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, i.e., the administered composition functions as a biological pacemaker.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Electronic and biological pacemaker systems
InactiveUS20080103537A1Modulating cardiac functionHeart stimulatorsCardiac pacemaker electrodeCardiac functioning
Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.
Owner:MEDTRONIC INC
Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
A composition for implantation into cardiac tissue includes a biological pacemaker that, when implanted, expresses an effective amount of a mutated hyperpolarization-activated and cyclic nucleotide-gated (HCN) isoform to modify Ih when compared with wild-type HCN. Methods for implementing each of the biological pacemakers include implanting each of biological pacemakers into cardiac tissue.
Owner:MEDTRONIC INC
Anisotropic biological pacemakers and av bypasses
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Biological pacemaker compositions and systems incorporating interstitial cells of cajal
InactiveUS20080103536A1Preventing cardiac pacingPreventing conduction dysfunctionElectrotherapyUnknown materialsCajal Interstitial CellsCardiac pacemaker electrode
A biological pacemaker composition for implantation into cardiac tissue includes an effective amount of interstitial cells of Cajal (ICC) to produce or conduct pacing stimuli and thereby modulate cardiac contraction. The biological pacemaker may be included as part of a heart pacing system that includes an implantable electric pacemaker for producing backup pacing stimuli if the at least one biological pacemaker is unable to modulate cardiac contraction at a predetermined pacing rate. Methods for preventing cardiac pacing or conduction dysfunction in a heart include implanting the biological pacemaker or the heart pacing system into the heart.
Owner:MEDTRONIC INC
Tandem cardiac pacemaker system
InactiveUS20090053180A1High basal signal frequencyLess negative maximum diastolic potentialBiocideGenetically modified cellsCardiac pacemaker electrodeCardiac pacemaker
This invention provides pacemaker systems comprising (1) an electronic pacemaker, and (2) a biological pacemaker, wherein the biological pacemaker comprises a cell that functionally expresses a chimeric hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channel at a level effective to induce pacemaker current in the cell. The invention also provides related biological pacemakers, atrioventricular bridges, methods of making same, and methods of treating a subject afflicted with a cardiac rhythm disorder.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +2
System And Method For Determining The Origin Of A Sensed Beat
InactiveUS20080281369A1Improve heart functionElectrocardiographyHeart stimulatorsLeft ventricular sizeNormal Sinus Rhythm
A method for monitoring a biological cardiac pacemaker is provided. The method may include stimulating a heart at a region selected for implantation of a biological pacemaker and sensing at least one electrical signal indicative of a cardiac depolarization originating in the region selected for implantation of the biological pacemaker. The method may further include sensing at least one subsequent electrical signal produced by the heart and determining if the subsequent electrical signal originated in the region selected for the biological pacemaker or another region of the heart. In an alternative embodiment, the method may include determining a template time difference between two points on cardiac complexes sensed in two or more different cardiac locations during normal sinus rhythm. The method may further include determining a time difference between two points on a subsequent cardiac complex sensed in two or more different cardiac locations. The time differences may be compared to determine if the subsequently-sensed cardiac complex originates in a left ventricular biological pacemaker site or in another cardiac site.
Owner:CARDIAC PACEMAKERS INC
Quantum dot labeled stem cells for use in providing pacemaker function
InactiveUS20090062876A1AbilityLack of perinuclear aggregationGenetically modified cellsBiological material analysisCardiac pacemaker electrodeFluorescence
The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Quantum dot labeled stem cells for use in providing pacemaker function
InactiveUS8170665B2AbilityLack of perinuclear aggregationElectrotherapyGenetically modified cellsCytosolCyclic nucleotide gated channels
The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Generation of biological pacemaker activity
Compositions and methods for enhancing hyperpolarization-activated cation inward current and disrupting inwardly rectifying potassium current of cells are described. The compositions and methods may be employed to cause the cells to become biological pacemaker cells, e.g. to become more like SA node cells, and to undergo spontaneous oscillating action potentials.
Owner:MEDTRONIC INC
Genetic modification of targeted regions of the cardiac conduction system
InactiveUS20100076063A1Organic active ingredientsCell receptors/surface-antigens/surface-determinantsCardiac dysfunctionPotassium channel
Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the bio-pacemaker composition increases expression of a channel or subunit thereof that produces funny current and a T-type Ca2+ channel or subunit thereof, and expresses one or more molecules that suppresses the expression of the wild type potassium channel.
Owner:MEDTRONIC INC
Genetic modification of targeted regions of the cardiac conduction system
InactiveUS20070021375A1Facilitating and restoring synchronous contractionCell receptors/surface-antigens/surface-determinantsSugar derivativesCardiac pacemaker electrodeWild type
Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the bio-pacemaker composition increases expression of a channel or subunit thereof that produces funny current and a T-type Ca2+ channel or subunit thereof, and expresses one or more molecules that suppresses the expression of the wild type potassium channel.
Owner:SHARMA VINOD +1
Delivery methods for a biological pacemaker minimizing source-sink mismatch
The present invention includes methods, systems, devices, and apparatus relating to minimizing source-sink mismatch associated with the application of a biological pacemaker in cardiac tissue. Stable and robust pacemaker activity is achieved by the application of the biological pacemaker at more than one site, in a linear pattern.
Owner:MEDTRONIC INC
Biological pacemaker model construction method and terminal device
The invention is applicable to the technical field of pacemaker modeling, and provides a biological pacemaker model construction method and a terminal device. The method comprises: constructing a model of inward rectifier potassium current ion channel, constructing a model of pacing current ion channel, according to the inward rectifier potassium current ion channel model, pacing current ion channel model and other ion channel models on the prestored ventricular myocyte membrane, reconstructing the biological pacemaker model to determine whether the electrophysiological characteristics of thebiological pacemaker model are qualified or not; and if the electrophysiological characteristics are qualified, judging that the biological pacemaker model is constructed successfully. The applicationof biological pacemaker is accelerated by using the scheme mentioned above, which has important guiding significance for the application of biological pacemaker in clinic.
Owner:SPACE INSTITUTE OF SOUTHERN CHINA (SHENZHEN)
Electronic and biological pacemaker systems
Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.
Owner:MEDTRONIC INC
Cardiac arrhythmia treatment methods and biological pacemaker
InactiveUS20110286931A1Effective therapyGuaranteed functionOrganic active ingredientsMedical devicesCardiac cellCardiac arrhythmia
Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, e.g., the administered composition functions as a biological pacemaker.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Method For Controlling Pacemaker Therapy
Owner:CARDIAC PACEMAKERS INC
Generation of biological pacemaker activity
Compositions and methods for enhancing hyperpolarization-activated cation inward current and disrupting inwardly rectifying potassium current of cells are described. The compositions and methods may be employed to cause the cells to become biological pacemaker cells, e.g. to become more like SA node cells, and to undergo spontaneous oscillating action potentials.
Owner:MEDTRONIC INC
Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
ActiveUS8076305B2BiocideCell receptors/surface-antigens/surface-determinantsBiochemistryCyclic nucleotide
A composition for implantation into cardiac tissue includes a biological pacemaker that, when implanted, expresses an effective amount of a mutated hyperpolarization-activated and cyclic nucleotide-gated (HCN) isoform to modify Ih when compared with wild-type HCN. Methods for implementing each of the biologocal pacemakers include implanting each of biologocal pacemakers into cardiac tissue.
Owner:MEDTRONIC INC
Biological Pacemaker
InactiveUS20120328584A1Modulate activity of endogenousConduct electricityOrganic active ingredientsBiocideCardiac pacemaker electrodeCardiac cell
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Engineered biological pacemakers
Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed.
Owner:UNIVERSITY OF PITTSBURGH +1
System and method for determining the origin of a sensed beat
ActiveUS20130238046A1Improve heart functionElectrocardiographyHeart stimulatorsLeft ventricular sizeCardiac pacemaker
A method for monitoring a biological cardiac pacemaker is provided. The method may include stimulating a heart at a region selected for implantation of a biological pacemaker and sensing at least one electrical signal indicative of a cardiac depolarization originating in the region selected for implantation of the biological pacemaker. The method may further include sensing at least one subsequent electrical signal produced by the heart and determining if the subsequent electrical signal originated in the region selected for the biological pacemaker or another region of the heart. In an alternative embodiment, the method may include determining a template time difference between two points on cardiac complexes sensed in two or more different cardiac locations during normal sinus rhythm. The method may further include determining a time difference between two points on a subsequent cardiac complex sensed in two or more different cardiac locations. The time differences may be compared to determine if the subsequently-sensed cardiac complex originates in a left ventricular biological pacemaker site or in another cardiac site.
Owner:CARDIAC PACEMAKERS INC
Cardiac arrhythmia treatment methods and biological pacemaker
InactiveUS20090175790A1Highly localized gene deliveryModulate activityOrganic active ingredientsElectrical testingCardiac pacemaker electrodeCardiac cell
Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, e.g., the administered composition functions as a biological pacemaker.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Use of late passage mesenchymal stem cells (MSCS) for treatment of cardiac rhythm disorders
InactiveUS20100049273A1Improve efficacyImprove securityBiocideElectrotherapyCardiac pacemaker electrodeMesenchymal stem cell
The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac rhythm disorders. The late passage MSCs of the invention may be used to provide biological pacemaker activity and / or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and / or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Method for controlling pacemaker therapy
The present invention includes a method for controlling pacemaker therapy in a patient with an implanted biological pacemaker. The method may include pacing a heart at a predetermined rate using an electronic pacemaker and configuring the pacemaker to periodically enter a biological pacemaker weaning mode. The weaning mode may include ceasing pacing for at least a predetermined length of time and monitoring the heart to detect electrical depolarizations of a ventricle of the heart during the predetermined length of time. The weaning mode may further include determining the length of time between the cessation of pacing and the detected electrical depolarization and determining if the length of time between the cessation of pacing and the detected electrical depolarization is less than a maximum predetermined interval. The pacemaker therapy may be withheld as long as the length of time is less than the maximum predetermined interval. Further, if the length of time exceeds a maximum interval, the pacemaker will exit the weaning mode.
Owner:CARDIAC PACEMAKERS INC
Compositions of late passage mesenchymal stem cells (MSCS)
InactiveUS20100047216A1Improve efficacyImprove securityBiocideGenetic material ingredientsActive proteinHeart disease
The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and / or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and / or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and / or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
System and method for determining the origin of a sensed beat
InactiveUS8442631B2Improve heart functionElectrocardiographyHeart stimulatorsCardiac pacemakerDepolarization
A method for monitoring a biological cardiac pacemaker. The method may include stimulating a heart at a region selected for implantation of a biological pacemaker and sensing at least one electrical signal indicative of a cardiac depolarization originating in the region selected for implantation of the biological pacemaker. The method may further include sensing at least one subsequent electrical signal produced by the heart and determining if the subsequent electrical signal originated in the region selected for the biological pacemaker or another region of the heart.
Owner:CARDIAC PACEMAKERS INC
Biological pacemaker model construction method and terminal device
The invention is applicable to the technical field of pacemaker modeling, and provides a biological pacemaker model building method and terminal equipment. The method comprises: constructing an inward rectifying potassium current ion channel model, constructing a pacing current ion channel model, reconstructing according to the inward rectifying potassium current ion channel model, the pacing current ion channel model and pre-existing models of other ion channels on the ventricular myocyte membrane Generate a biological pacemaker model, judge whether the electrophysiological characteristics of the biological pacemaker model are qualified, and determine whether the biological pacemaker model is successfully constructed if the electrophysiological characteristics are judged to be qualified. After adopting the above scheme, the application process of the biological pacemaker is accelerated, which has important guiding significance for the clinical application of the biological pacemaker.
Owner:深圳市绿航星际太空科技有限公司
Biological Pacemakers Incorporating HCN2 and SkM1 Genes
InactiveUS20160333071A1Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsIn vivoCyclic nucleotide
It is demonstrated that hyperpolarization-activated cyclic nucleotide-gated (HCN)-based biological pacing, especially that achieved by transduction of the HCN2 gene into cardiac cells in vivo, was significantly improved by co-transduction of the skeletal muscle sodium channel 1 (SkMI) gene. Expression of both genes hyperpolarized the action potential (AP) threshold. When viral biological pacemaker constructs carrying genes for HCN2 and SkMI were injected into the heart of dogs in vivo, the pacemaker function was facilitated by the slow depolarizing HCN2 current and the hyperpolarized AP threshold generated by SkMI. This dual gene therapy provided both highly efficient pacing and a brisk autonomic response that is superior to those of previously developed gene- or cell-based approaches.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +2
A method of inducing differentiation of induced pluripotent stem cells into sinoatrial node pacemaker cells
ActiveCN115851581BSkeletal/connective tissue cellsForeign genetic material cellsHuman Induced Pluripotent Stem CellsPacemaker cell
A novel method for inducing differentiation of induced pluripotent stem cells into sinoatrial node pacemaker cells, by adding small molecule compounds U0126 and RA in the culture medium during in vitro differentiation process to control the differentiation direction of iPS cells, taking Shox2 as a marker for sinoatrial node head pacemaker cells, and taking Shox2 and Nkx2.5 as markers for sinoatrial node junction and intermodal bundle pacemaker cells to monitor the differentiation process of cells, can effectively induce two pacemaker cell subtypes with uniform phenotype and consistent electrophysiological characteristics. The study of directional induction of mouse iPS cells into two pacemaker cell subtypes provides a research basis for exploring the directional induction of human iPS cells into two pacemaker cell subtypes, screening small molecule compounds that can promote the directional differentiation of iPS cells into specific types of pacemaker cells, and providing uniform, stable and reliable stem cell sources for the preparation of biological pacemakers.
Owner:GUIZHOU MEDICAL UNIV